NMP4, an Arbiter of Bone Cell Secretory Capacity and Regulator of Skeletal Response to PTH Therapy

AbstractThe skeleton is a secretory organ, and the goal of some osteoporosis therapies is to maximize bone matrix output.Nmp4 encodes a novel transcription factor that regulates bone cell secretion as part of its functional repertoire. Loss ofNmp4 enhances bone response to osteoanabolic therapy, in part, by increasing the production and delivery of bone matrix.Nmp4 shares traits with scaling factors, which are transcription factors that influence the expression of hundreds of genes to govern proteome allocation for establishing secretory cell infrastructure and capacity.Nmp4 is expressed in all tissues and while global loss of this gene leads to no overt baseline phenotype, deletion ofNmp4 has broad tissue effects in mice challenged with certain stressors. In addition to an enhanced response to osteoporosis therapies,Nmp4-deficient mice are less sensitive to high fat diet-induced weight gain and insulin resistance, exhibit a reduced disease severity in response to influenza A virus (IAV) infection, and resist the development of some forms of rheumatoid arthritis. In this review, we present the current understanding of the mechanisms underlyingNmp4 regulation of the skeletal response to osteoanabolics, and we discuss how this unique gene contributes to the diverse phenotypes among different tissues and stresses. An emerging theme is thatNmp4 is important for the infrastructure and capacity of secretory cells that are critical for health and disease.
Source: Calcified Tissue International - Category: Orthopaedics Source Type: research